Translational to Phase 1 Clinical Data for Darlifarnib + Adagrasib in Advanced KRAS G12C Solid Tumors: Results from FIT-001
- Adaptive resistance to KRAS G12C inhibition: MAPK pathway reactivation remains a key driver limiting depth and durability of response
- Targeting this vulnerability: Combination darlifarnib + adagrasib enhances pathway suppression and overcomes resistance across KRAS G12C preclinical models
- Clinical translation (FIT-001 clinical trial): Early Phase 1a data show manageable safety and encouraging preliminary antitumor activity supporting darlifarnib + KRASi as a combination strategy across solid tumors, including advanced CRC, PDAC and NSCLC